Siemens Healthineers

TORONTO – October 31, 2026 -- Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has signed a supply and distribution agreement with the iMRI Division of Cook Medical, adding a second U.S. capital equipment channel for its TULSA-PRO system while keeping recurring treatment kit and service revenue in-house.

Cook buys systems at a predetermined transfer price and resells them in the U.S.

Cook will purchase TULSA-PRO systems from Profound at a predetermined transfer price for U.S. distribution. Customers who buy through Cook will source single-use disposables and service contracts directly from Profound. The company therefore keeps the recurring revenue relationship on every system Cook places.

Profound's existing capital sales team will keep selling TULSA-PRO directly to sites with compatible MRI systems. The two channels target different buyers: hospitals using existing MRI infrastructure and those investing in new iMRI capabilities.

Sheridan – October 16, 2026 -- The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach USD 41.5 billion by 2031, a CAGR of 7.2%, according to a new study by Wissen Research.

Demand starts with patient volume. The International Agency for Research on Cancer counted about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and expects annual new cases to pass 35 million by 2050. Each patient may need screening, diagnosis, staging, molecular characterization and follow-up.

Sheridan, Wyo. – October 05, 2026 -- The global in vitro diagnostics (IVD) quality control market is set to climb from $1.7 billion in 2026 to $2.2 billion by 2031, a 5.3% compound annual growth rate, according to a new study by Wissen Research.

Rising testing volumes and regulatory pressure push labs toward automated QC

Growth is driven by expanding testing complexity across clinical chemistry, immunoassay, hematology, and molecular diagnostics, combined with tightening regulatory requirements such as CLIA in the United States. Laboratories are increasingly adopting internal quality controls, third-party control materials, and external quality assessment programs as standard practice.

Sheridan, Wyo. – September 19, 2026 -- The global diagnostic imaging market will expand from $26.5 billion in 2026 to $33.2 billion by 2031, a 4.6% compound annual growth rate, according to a new study by Wissen Research.

AI moves inside the scanner, cutting exam times sharply

Deep learning reconstruction algorithms are now embedded directly into image acquisition pipelines rather than applied after scanning. GE HealthCare's Sonic DL sequence allows complex multi-sequence brain and joint MRI protocols to complete in under 15 minutes, letting hospitals raise per-scanner throughput without new capital equipment. Radiology remains the top specialty for AI device clearances, with more than 1,100 cleared by the U.S. FDA to date.

SHERIDAN, WYOMING - April 04, 2026 - Radiation-free soft tissue imaging is now clinically validated and FDA-cleared for in-clinic dental diagnostics, shifting the diagnostic standard beyond cone-beam CT and X-ray for periodontitis, TMJ disorders, endodontics, and orthodontics assessment. The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona in partnership with Siemens Healthineers, is the world's first dental-dedicated MRI (ddMRI) system, and its clearance marks a structural change in what diagnostic workflows dental practices can deploy independently - without referral to external radiology centers.

SHERIDAN, WYOMING - April 04, 2026 - Dental diagnostic practice faces a structural shift as the first commercially positioned dental-dedicated MRI (ddMRI) clears FDA review, enabling clinicians to visualize soft tissue, nerves, cartilage, and active inflammation without ionizing radiation - capabilities no CBCT or conventional X-ray system can match. The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona in collaboration with Siemens Healthineers, now holds FDA clearance following validation in a clinical trial, placing radiation-free soft tissue diagnostics within reach of in-clinic dental settings for the first time.